Endocare — CJS Securities 4th Annual "New Ideas" Small Cap Investor Conference 2004
7 slides from Endocare's conference presentation, Aug 17, 2004
Slide 1: Endocare, Inc. CJS Securities 4th Annual "New Ideas" Small Cap Investor Conference
Endocare, Inc. CJS Securities, Inc. 4th Annual "New Ideas" Small Cap Investor Conference August 17, 2004
Slide 2: Company Background
Company Background Endocare is an innovative public medical device company focused on the development of minimally invasive technologies for tissue & tumor ablation and erectile dysfunction. The Company has a strong intellectual property position for its unique technologies that harnesses the powerf
Slide 3: Cryocare TCAP Procedure (Targeted Ablation of the Prostate)
Cryocare TCAP Procedure (Targeted Ablation of the Prostate) Minimally invasive procedure that uses ice to destroy prostate cancer. Requires no radiation beams, no permanent radiation seeds and no radiation exposure. Unique "visualization" of the ice ball under ultrasound unlike other ablation treatm
Slide 4: Technology
Technology - Fully integrated planning, placement and treatment - Designed to be physician user-friendly - Designed to be physician user-friendly - Designed to be physician user-friendly - Designed to be physician user-friendly - Designed to be physician user-friendly - Designed to be physician user
Slide 5: Endocare Management
Endocare Management Craig T. Davenport - CEO & Chairman - Chief Executive Officer since December 2003; Chairman since January 2004 - 1994 to 2003 CEO & Managing Partner of The D.W. Group Private investment company - 1985 to 1993 President & COO of Tokos Medical Corporation (NASDAQ) Medical device ma
Slide 6: Company Highlights
Company Highlights: · Annual growth in procedures 45%+ in markets where overall penetration is less than 3%. Proven & experienced management team. Clinically proven technology in prostate cancer with strong IP positioning and patent protection. $400 million + growing market in prostate cancer. · $75
Slide 7: Closing 2004 & into 2005
Closing 2004 & into 2005 Some of our critical objectives: Remain SEC compliant with our financial reporting. Become compliant with Section 404 of Sarbanes-Oxley legislation by year-end. Get the trading of our stock back on a national exchange. Resolve shareholder lawsuits. Satisfactorily resolve the